Literature DB >> 33634020

Potential Clinical Significance of Overall Targeting Accuracy and Motion Management in the Treatment of Tumors That Move With Respiration: Lessons Learnt From a Quarter Century of Stereotactic Body Radiotherapy From Dose Response Models.

Anand Mahadevan1, Bahman Emami2, Jimm Grimm1, Lawrence R Kleinberg3, Kristin J Redmond3, James S Welsh2, Robert Rostock1, Eric Kemmerer1, Kenneth M Forster1, Jason Stanford1, Sunjay Shah4, Sucha O Asbell5, Tamara A LaCouture5, Carla Scofield1, Ian Butterwick1, Jinyu Xue6, Alexander Muacevic7, John R Adler8.   

Abstract

OBJECTIVE: To determine the long-term normal tissue complication probability with stereotactic body radiation therapy (SBRT) treatments for targets that move with respiration and its relation with the type of respiratory motion management (tracking vs. compression or gating).
METHODS: A PubMed search was performed for identifying literature regarding dose, volume, fractionation, and toxicity (grade 3 or higher) for SBRT treatments for tumors which move with respiration. From the identified papers logistic or probit dose-response models were fitted to the data using the maximum-likelihood technique and confidence intervals were based on the profile-likelihood method in the dose-volume histogram (DVH) Evaluator.
RESULTS: Pooled logistic and probit models for grade 3 or higher toxicity for aorta, chest wall, duodenum, and small bowel suggest a significant difference when live motion tracking was used for targeting tumors with move with respiration which was on the average 10 times lower, in the high dose range.
CONCLUSION: Live respiratory motion management appears to have a better toxicity outcome when treating targets which move with respiration with very steep peripheral dose gradients. This analysis is however limited by sparsity of rigorous data due to poor reporting in the literature.
Copyright © 2021 Mahadevan, Emami, Grimm, Kleinberg, Redmond, Welsh, Rostock, Kemmerer, Forster, Stanford, Shah, Asbell, LaCouture, Scofield, Butterwick, Xue, Muacevic and Adler.

Entities:  

Keywords:  dose response; normal tissue complication probability; radiosurgery; stereotactic body radiation therapy; tracking

Year:  2021        PMID: 33634020      PMCID: PMC7900559          DOI: 10.3389/fonc.2020.591430

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  68 in total

1.  Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy.

Authors:  Clint Park; Lech Papiez; Shichuan Zhang; Michael Story; Robert D Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-01       Impact factor: 7.038

2.  Stereotactic ablative radiotherapy in the framework of classical radiobiology: response to Drs. Brown, Diehn, and Loo.

Authors:  Jeffrey Meyer; Robert Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-01       Impact factor: 7.038

3.  Dose Tolerance for Stereotactic Body Radiation Therapy.

Authors:  Jimm Grimm
Journal:  Semin Radiat Oncol       Date:  2015-12-03       Impact factor: 5.934

Review 4.  The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?

Authors:  J Martin Brown; David J Carlson; David J Brenner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-02-01       Impact factor: 7.038

5.  Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer.

Authors:  Robert W Mutter; Fan Liu; Andres Abreu; Ellen Yorke; Andrew Jackson; Kenneth E Rosenzweig
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-08-23       Impact factor: 7.038

6.  External stereotactic irradiation by linear accelerator.

Authors:  F Colombo; A Benedetti; F Pozza; R C Avanzo; C Marchetti; G Chierego; A Zanardo
Journal:  Neurosurgery       Date:  1985-02       Impact factor: 4.654

7.  A new approach for direct CT localization in stereotaxis.

Authors:  J L Barcia-Salorio; J Broseta; G Hernandez; P Roldan; V Bordes
Journal:  Appl Neurophysiol       Date:  1982

8.  Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer.

Authors:  J Martin Brown; Maximilian Diehn; Billy W Loo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-01       Impact factor: 7.038

9.  Analysis of clinical complication data for radiation hepatitis using a parallel architecture model.

Authors:  A Jackson; R K Ten Haken; J M Robertson; M L Kessler; G J Kutcher; T S Lawrence
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-02-15       Impact factor: 7.038

10.  Unexpected changes of rat cervical spinal cord tolerance caused by inhomogeneous dose distributions.

Authors:  Hendrik P Bijl; Peter van Luijk; Rob P Coppes; Jacobus M Schippers; Antonius W T Konings; Albert J van der Kogel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-09-01       Impact factor: 7.038

View more
  1 in total

1.  Adoption of respiratory motion management in radiation therapy.

Authors:  Alex Burton; Sabeena Beveridge; Nicholas Hardcastle; Jessica Lye; Masoumeh Sanagou; Rick Franich
Journal:  Phys Imaging Radiat Oncol       Date:  2022-09-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.